Citations

Clear

126 citation(s) found for "Soliman, EZ".

Dual hypothermic oxygenated machine perfusion of the liver reduces post-transplant biliary complications: a retrospective cohort study
Dingfelder, Jule , Riha, Moriz, Kacar, Sertac, Rauter, Laurin , Becker, Nikolaus , Zadeh, Tina Saffarian, Tortopis, Chiara, Silberhumer, Gerd R. , Soliman, Thomas , Gyöeri, Georg , Pereyra, David , Gyoeri, Georg P , Pereyra, David , Becker, Nikolaus, Starlinger, Patrick , Ristl, Robin , Salat, Andreas , Berlakovich, Gabriela , Györi, Georg

Mayo Clinic

International Journal of Surgery | October 18, 2024 | Volume: 110 | Issue: 12 | Pages: 7909-7918

10.1097/js9.0000000000002115 | PMID 39422535 Get It

Background: Corroborating evidence for the use of hypothermic oxygenated machine perfusion (HOPE) prior to orthotopic liver transplantation (OLT) suggests a beneficial effect in regard to biliary complications. Here, the authors aim to evaluate whether perfusion via portal vein alone (sHOPE) or via additional perfusion of the hepatic artery (dHOPE) have diverging impact on outcomes after OLT when compared to the use of static cold storage (SCS). Methods: Consecutive patients undergoing OLT at the Medical University of Vienna (2018–2023) were retrospectively analyzed. Donor organs were procured using SCS, or subjected to end-ischemic sHOPE or dHOPE. The severity of biliary complications was classified according to the degree of therapeutic intervention (endoscopic retrograde cholangiopancreatography or surgical revision). Results: Two hundred forty-seven patients were included (69 SCS, 76 sHOPE, and 102 dHOPE). Hospitalization was shorter for patients after HOPE (median in days: SCS=25 vs HOPE=20, P=0.019). Biliary complications were less frequent in patients after HOPE (SCS=37.7% vs HOPE=22.5%, P=0.015). A significantly lower incidence of surgical revisions for biliary complications was observed in the HOPE cohort (24.6% vs 11.8%, P=0.012). When evaluating outcome according to HOPE-modality, a significant reduction in biliary complications (P=0.006) and surgical revisions (P=0.002) was only observed in dHOPE patients in comparison to SCS. Further, only dHOPE was significantly associated with a reduced need for surgical revision for biliary complications upon univariable and multivariable logistic regression (odds ratio=0.336, P=0.011). Conclusion: HOPE leads to a reduction of biliary complications and associated surgical revisions. This effect seems to be primarily associated with use of dHOPE, while both methods appear as feasible options for preconditioning of donor grafts prior to OLT.
Barriers to global engagement for African researchers: A position paper from the Alliance for Medical Research in Africa (AMedRA)
Gaye, Bamba , Singh, Gurbinder , Gaye, Ngone Diaba, Ka, Mame Madjiguène , Seck, Daouda, Gueye, Khadidiatou, Kitara, David Lagoro , Lassale, Camille , Anne, Malick, Diaw, Mor , Gaye, Magaye, Fall, Abdou Salam , Diongue, Aïda, Seck, Ibrahima , Belkhadir, Jamal , Wone, I, Gueye, Sérigne Maguèye , Sow, Papa Salif , Kohen, Jamal Eddine, Vogelsang, Dorothea, Mbaye, Maïmouna Ndour, Liyong, Elisabeth Alice, Kengne, André Pascal , Sougou, Ndèye Mariéme, Ba, Awa, Tukakira, John, Lorenz, Thiess , Kabore, Elisé , Muzumala, Malaizyo Gabriel, Olanrewaju, A. I., Jaiteh, Lamin , Délicat-Loembet, Lucrèce M. , Alson, Aimée Olivat Rakoto, Niang, Khadim, Mwebaze, Ernest , Nakatumba‐Nabende, Joyce , Machuve, Dina , Adie, Prestone, Hanne, Fatoumata, Sougou, Marième, Koffi, Kouassi Gustave, Luwanda, Lameck, Mekonnen, Demeke, Ebeid, Fatma Soliman Elsayed , Enama, Jean Paul, Zeba, Mohamadi , Guedou, Fernand Aimé, Mbélesso, Pascal , Carter, Jennifer , Coulibaly, Bakary, Dramé, Mohamed Lamine, Mouanga, Alain Maxime , Lacroix, Philippe, Diagana, Mouhamadou , Ekouévi, Didier Koumavi , Houinato, Dismand, Faye, Adama , Wambugu, Vivien , Kamaté, Jean, Lalika, Mathias , Ale, Boni Maxime , Fall, Ibrahima Socé , Samb, Abdoulaye, Jobe, Modou , Isiozor, Nzechukwu Michael , Gaye, Ngone Diaba, Seck, Daouda , Seck, Sidy Mohamed , Sow, Abdourahmane , Diongue, Aïda, Lamptey, Roberta , Sobngwi, Eugène , Muzumala, Malaizyo G. , Maina, Ciira wa , Adie, Prestone, Tine, Roger Clément Kouly , Koffi, K. G. , Sattler, Elisabeth Lilian Pia , Enama, Jean-Paul, Coulibaly, Bakary, Preux, Pierre‐Marie , Nsoesie, Elaine Okanyene , Tshilolo, Léon Muepu

Mayo Clinic

Journal of Global Health | October 18, 2024 | Volume: 14 | Issue: No issue available | Pages: No page available

10.7189/jogh.14.03042 | PMID 39421942 Get It

Potential roles for artificial intelligence in clinical microbiology from improved diagnostic accuracy to solving the staffing crisis
Soliman, Amr , Marouf, Mohamed , Pancholi, Preeti , Graf, Erin, Soliman, Amr , Marouf, Mohamed , Graf, Erin H. , Parwani, Anil Vasdev

Mayo Clinic

American Journal of Clinical Pathology | August 13, 2024 | Volume: 163 | Issue: 2 | Pages: 162-168

10.1093/ajcp/aqae107 | PMID 39136261 Get It

Abstract Objectives This review summarizes the current and potential uses of artificial intelligence (AI) in the current state of clinical microbiology with a focus on replacement of labor-intensive tasks. Methods A search was conducted on PubMed using the key terms clinical microbiology and artificial intelligence. Studies were reviewed for relevance to clinical microbiology, current diagnostic techniques, and potential advantages of AI in routine microbiology workflows. Results Numerous studies highlight potential labor, as well as diagnostic accuracy, benefits to the implementation of AI for slide-based and macroscopic digital image analyses. These range from Gram stain interpretation to categorization and quantitation of culture growth. Conclusions Artificial intelligence applications in clinical microbiology significantly enhance diagnostic accuracy and efficiency, offering promising solutions to labor-intensive tasks and staffing shortages. More research efforts and US Food and Drug Administration clearance are still required to fully incorporate these AI applications into routine clinical laboratory practices.
Transvenous embolization of cerebrospinal fluid-venous fistulas: A comprehensive technical video guide
Oushy, Soliman , Borg, Nicholas , Brinjikji, Waleed , Oushy, Soliman H

Mayo Clinic

Interventional Neuroradiology | August 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241264859 | PMID 39129242 Get It

Cerebrospinal fluid (CSF)-venous fistulas necessitate a comprehensive understanding of spinal venous anatomy for successful embolization. 1 This video details the essential technical and anatomical nuances of CSF-venous fistula embolization at various spinal levels, including the cervical, thoracic, and lumbar spine. Precise microcatheter navigation, guided by a detailed understanding of spinal venous anatomy, is crucial for reaching the fistula site and successful treatment. Embolization typically focuses on the foraminal vein, paraspinal vein, and lateral epidural plexus, aiming to create a comprehensive liquid embolic plug. 2 As experience with this procedure grows, continued refinement of techniques and exploration of optimal access routes will further enhance success rates.
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, William J. , Moran, Meena S. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Anderson, Bethany , Bailey, Janet E., Burstein, Harold J. , Chen, Nan , Chew, Helen K. , Dang, Chau T. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Lyons, Janice A., McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Santa‐Maria, Cesar A. , Schneider, Bryan P. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Wei, Mei , Wisinski, Kari B. , Yeung, Kay T. , Schonfeld, Ryan, Telli, Melinda L , Abramson, Vandana G. , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Mortimer, Joanne , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Soliman, Hatem Hussein , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 26, 2024 | Volume: 22 | Issue: 5 | Pages: 331-357

10.6004/jnccn.2024.0035 | PMID 39019058 Get It

Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org .
Stereotactic depth electrode placement for chronic subthreshold cortical stimulation: surgical technique video
Harrison, Daniel , Oushy, Soliman , Harrison, Daniel Jeremiah, Oushy, Soliman H , Gregg, Nicholas M. , Lundstrom, Brian N. , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgical Focus: Video | July 3, 2024 | Volume: 11 | Issue: 1 | Pages: V10

10.3171/2024.4.focvid2422 | PMID 38957423 Get It

Neurostimulation is an increasingly common treatment option for medically intractable epilepsy. SANTE (Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy) and Responsive Neurostimulation (RNS) System are landmark neurostimulation trials that utilized either duty cycle or a responsive stimulation paradigm. A seizure-free outcome is rarely observed with responsive and duty cycle neurostimulation devices. Chronic subthreshold cortical stimulation (CSCS) is a promising treatment for adult drug-resistant epilepsy involving eloquent cortex and has demonstrated safety and efficacy. Herein, the authors describe the surgical technique as well as details of stimulation programming involved in CSCS placement to facilitate the adoption of this promising treatment. The video can be found here: https://stream.cadmore.media/r10.3171/2024.4.FOCVID2422
Impact of Obesity on Timing of Tracheotomy: A Multi‐institutional Retrospective Study
Yousef, Andrew , Soliman, Shady , Panuganti, Bharat , Francis, David O. , Klebaner, Dasha, Asturias, Alicia , Alattar, Ali , Wood, Samuel , Terry, M. C. , Bryson, Paul C. , Tipton, Courtney B. , Zhao, Elise E. , Maria, Chloe Santa , Sung, C. Kwang , Lao, Wilson P. , Thompson, Jordan M. , Crawley, Brianna K. , Rosen, Sarah P. , Berezovsky, Anna , Hennesy, Theresa B. , Joseph, Ian T. , Sarhadi, Kamron, Kuhn, Maggie A. , Abdel‐Aty, Yassmeen , Kennedy, Maeve M. , Weissbrod, Philip A. , Soliman, Shady I , Pang, John , Wood, Samuel , Terry, Morgan , O'Rourke, Ashli , Grimm, David R , Sung, C K , Crawley, Brianna K , Rosen, Sarah , Berezovsky, Anna , Clary, Matthew S , Abdel-Aty, Yassmeen, Lott, David G , Weissbrod, Philip A , Solomon, Isaac, Grimm, David R. , Kupfer, Robbi A. , Clary, Matthew S. , Lott, David G.

Mayo Clinic

The Laryngoscope | June 19, 2024 | Volume: 134 | Issue: 11 | Pages: 4674-4681

10.1002/lary.31586 | PMID 38895915 Get It

Objective To examine the impact of increased body mass index (BMI) on (1) tracheotomy timing and (2) short‐term surgical complications requiring a return to the operating room and 30‐day mortality utilizing data from the Multi‐Institutional Study on Tracheotomy (MIST). Methods A retrospective analysis of patients from the MIST database who underwent surgical or percutaneous tracheotomy between 2013 and 2016 at eight institutions was completed. Unadjusted and adjusted logistic regression analyses were used to assess the impact of obesity on tracheotomy timing and complications. Results Among the 3369 patients who underwent tracheotomy, 41.0% were obese and 21.6% were morbidly obese. BMI was associated with higher rates of prolonged intubation prior to tracheotomy accounting for comorbidities, indication for tracheotomy, institution, and type of tracheostomy ( p = 0.001). Morbidly obese patients (BMI ≥35 kg/m 2 ) experienced a longer duration of intubation compared with patients with a normal BMI (median days intubated [IQR 25%–75%]: 11.0 days [7–17 days] versus 9.0 days [5–14 days]; p < 0.001) but did not have statistically higher rates of return to the operating room within 30 days ( p = 0.12) or mortality ( p = 0.90) on multivariable analysis. This same finding of prolonged intubation was not seen in overweight, nonobese patients when compared with normal BMI patients (median days intubated [IQR 25%–75%]: 10.0 days [6–15 days] versus 10.0 days [6–15 days]; p = 0.36). Conclusion BMI was associated with increased duration of intubation prior to tracheotomy. Although morbidly obese patients had a longer duration of intubation, there were no differences in return to the operating room or mortality within 30 days. Level of Evidence 3 Laryngoscope , 134:4674–4681, 2024
Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study.
Oh, Do‐Youn , Rorive, Andrée, Takahashi, Shunji , Monk, Bradley J. , Reck, Martin , Ramos, Jorge , Tan, Sherry, Stinchcombe, Tom, Okines, Alicia , Curigliano, Giuseppe , Mizuno, Nobumasa , Soliman, Hatem Hussein , Bekaii‐Saab, Tanios , Hamilton, Erika , Nakamura, Yoshiaki , Nguyen, Danny , O’Malley, David M. , Yu, Evan Y , Stinchcombe, Thomas E. , Pohlmann, Paula R.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 1105-1105

10.1200/jco.2024.42.16_suppl.1105 Get It

1105 Background: Approximately 2-5% of breast cancers harbor HER2 mutations, often occurring in hormone receptor-positive (HR+) disease. There are currently no approved treatment options for patients (pts) with HER2-mutated metastatic breast cancer (HER2-mut MBC). Tucatinib (TUC) is a tyrosine kinase inhibitor highly selective for HER2 and is approved for previously treated HER2+ MBC with or without brain metastases in combination with trastuzumab (Tras) and capecitabine. Here, we report the efficacy and safety results of TUC combined with Tras in pts with previously treated HER2-mut MBC. Methods: SGNTUC-019 (NCT04579380) is an open-label phase 2 basket study evaluating efficacy, safety, and tolerability of TUC and Tras in pts with metastatic HER2-altered solid tumors. Pts in the HER2-mut MBC cohort must have HER2 mutations determined locally by tissue- or blood-based next-generation sequencing, not be HER2+ per local testing, been previously treated with ≥1 systemic therapy in the locally advanced, unresectable, or metastatic setting, and if HR+, have received a CDK4/6 inhibitor. Pts were treated in 21-day cycles with TUC (300 mg orally twice a day) and Tras (8 mg/kg IV followed by 6 mg/kg every 3 wks). Pts with HR+ disease also received fulvestrant (F; 500 mg IM once every 4 wks starting from cycle 1 day 1, and cycle 1 day 15). Disease status was determined based on RECIST v1.1 with assessments performed every 6 wks for 24 wks and every 12 wks thereafter. The primary endpoint is cORR per investigator assessment. Secondary endpoints include OS, DCR, DOR, PFS, and safety. Results: As of Nov 1, 2023, 31 pts were enrolled in the HER2-mut MBC cohort. The median duration of follow-up for OS was 15.0 months. Twenty-seven (87%) pts had HR+ disease and 18 (58%) had lobular histology. The pts received a median of 4 prior lines of systemic therapy in any setting. cORR was 41.9% (90% CI, 26.9-58.2) with 13 responses including 2 complete responses. Median DOR was 12.6 months (90% CI, 4.7, not estimable), DCR was 80.6% (n=25; 90% CI, 65.3-91.2), median PFS was 9.5 months (90% CI, 5.4-13.8), and median OS was 20.1 months (90% CI, 15.9 to not estimable). The most common treatment-emergent adverse events (TEAEs) reported were diarrhea (64.5%) and nausea (35.5%). The most common grade ≥3 TEAEs reported were diarrhea (13%), alanine aminotransferase increase (10%), and hypertension (10%). Two (6.5%) pts discontinued TUC due to TEAEs, but these pts continued Tras. No deaths were due to TEAEs. Additional biomarker analyses will be included in the presentation. Conclusions: The investigational combination of TUC and Tras, plus F in pts with HR+ disease, was well tolerated and had clinical activity in pts with previously treated HER2-mut MBC. The results support further evaluation of the combination of TUC and Tras as a potential treatment option for this pt population. Clinical trial information: NCT04579380 .
Meta-Analysis of Antibiotic and Non-Antibiotic Lock Solutions for Prevention of Hemodialysis Catheter-Related Infections
Salim, Sohail Abdul , Cheungpasitporn, Wisit, Tapolyai, Mihály , Zsom, Lajos , Cheungpasitporn, Wisit , Thongprayoon, Charat , Soliman, Karim , Fülöp, Tibor

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 442-443

10.1681/asn.20203110s1442c Get It

Low-profile mechanical thrombectomy devices for large vessel occlusion in pediatric ischemic stroke
Oushy, Soliman , Garton, Andrew , See, Alfred P. , Oushy, Soliman H , Orbach, Darren B.

Mayo Clinic

Journal of NeuroInterventional Surgery | May 6, 2024 | Volume: 17 | Issue: 6 | Pages: 620-624

10.1136/jnis-2024-021574 | PMID 38719443 Get It

Background Mechanical thrombectomy (MT) is a well-established treatment modality for large vessel occlusion (LVO) in adults, but there are limited data in the pediatric population. The rarity of the condition makes prospective trial design difficult, and therefore evaluation of MT devices and outcomes is sparse. In pediatric LVO cases, some newer devices may be appropriate for use in revascularization procedures. Furthermore, illustrative specific device-access combinations have rarely been presented in young patients under the age of 5 years. Methods This was a single institution experience in intracranial MT procedures for pediatric acute ischemic stroke (AIS). A given procedure was included if there was an attempt at MT between 2015 and 2023. Results Sixteen endovascular procedures were performed in 15 patients with AIS, with a mean age of 7.4 years; eight patients were <5 years of age. MT was attempted in 15/16 (93.7%) procedures, including 11 (73.3%) in the anterior circulation and four (26.7%) in the posterior circulation; one case recanalized after medical treatment. The most common MT techniques were combined aspiration with a stentriever (n=10, 66.7%) and aspiration alone (n=3, 20%). Traditional stentrievers (4–6 mm) were used in seven cases and low-profile stentrievers in four cases. Improved reperfusion was achieved in all low-profile stentriever cases. Reperfusion of modified Thrombolysis in Cerebral Infaction ≥2b was obtained in 73.3% of cases, including 72.7% of those in which a stentriever was used. Conclusions Low-profile thrombectomy devices may achieve similar revascularization results to other approaches in challenging clinical scenarios observed in younger children.